Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Table 3 Baseline predictive factors for cure of ulcerative lesions by multivariate analysis

Variables	Univariate logistic regression			Multiple logistic regression
Variables	Wald	P	OR (95%CI)	Wald	P	OR (95%CI)
Male	0.4814	0.4878	0.70 (0.25–1.93)
Age (years)	0.3122	0.5763	0.99 (0.96–1.01)
Disease duration (entero-BD)	0.3496	0.5543	0.99 (0.99–1.00)
Multiple ulceration	1.5773	0.2091	1.96 (0.69–5.61)
History of relapse	0.0121	0.9121	0.95 (0.36–2.48)
History of perforation	4.0542	0.0345	0.23 (0.05–0.96)	2.4664	0.1163	0.28 (0.06–1.38)
History of surgery	1.8818	0.1701	0.35 (0.08–1.58)
Concomitant CS use	0.5943	0.4407	1.46 (0.56–3.84)
Concomitant CS dose (mg/day)	0.07655	0.7820	1.00 (0.98–1.03)
Concomitant colchicine use	5.4007	0.0201	3.45 (1.21–9.80)	2.7596	0.0967	2.74 (0.73–8.99)
Concomitant drugs use (MTX, MS/SSZ, AZ)	3.4411	0.1007	3.44 (0.68–17.3)
Concomitant MTX use	5.4008	0.0201	3.45 (1.21–9.80)	0.2392	0.6247	1.48 (0.30–7.23)
TNF-i use	7.6116	0.0017	6.60 (1.73–25.2))	3.8795	0.0416	6.17 (1.01–37.8)
DAIBD	0.5470	0.4595	1.01 (0.99–1.02)

Model χ² test P = 0.0040. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease

ISSN: 1478-6362